Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

June 4, 2019

Study Completion Date

May 11, 2021

Conditions
Retinopathy of Prematurity
Interventions
DRUG

Bevacizumab

Varying dosages in 10µl

Trial Locations (11)

21287

Wilmer Institute, Baltimore

23502

Virginia Pediatric Eye Center, Norfolk

27710

Duke University Eye Center, Durham

30322

The Emory Eye Center, Atlanta

43205

Pediatric Ophthalmology Associates, Inc., Columbus

45229

Cincinnati Children's Hospital, Cincinnati

46202

Riley Hospital for Children, Indianapolis

73104

Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City

77030

Texas Children's Hospital - Dept. Of Ophthalmology, Houston

84132

University of Utah Moran Eye Center, Salt Lake City

02115

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

Pediatric Eye Disease Investigator Group

NETWORK

collaborator

National Eye Institute (NEI)

NIH

lead

Jaeb Center for Health Research

OTHER